Skip to main content
SLSN
NASDAQ Life Sciences

Solésence Reports Record $62.1M Revenue for 2025, Full-Year Net Income Halves

feedReported by GlobeNewswire
Sentiment info
Neutral
Importance info
8
Price
$0.9
Mkt Cap
$63.49M
52W Low
$0.78
52W High
$16.56
Market data snapshot near publication time

summarizeSummary

Solésence reported mixed financial results for the fourth quarter and full-year 2025. The company achieved record full-year revenue of $62.1 million, a 19% increase year-over-year, driven by growth in consumer products. However, full-year net income significantly declined to $1.8 million from $4.2 million in 2024, and gross margin compressed from 31% to 26%. For the fourth quarter, revenue was flat at $12.5 million, but the company swung to a net income of $0.2 million from a $0.6 million loss in the prior year period, with gross margin improving to 27%. Management highlighted a new strategic initiative, "Transform & Transcend," aimed at driving sustainable, profitable growth. Traders will be watching if the Q4 profitability improvements can be sustained and if the strategic initiatives can reverse the full-year margin and net income declines.

في وقت هذا الإعلان، كان SLSN يتداول عند ‏٠٫٩٠ US$ في NASDAQ ضمن قطاع Life Sciences، مع قيمة سوقية تقارب ٦٣٫٥ مليون US$. تراوح نطاق التداول خلال 52 أسبوعًا بين ‏٠٫٧٨ US$ و‏١٦٫٥٦ US$. تم تقييم هذا الخبر على أنه ذو معنويات سوقية محايدة وبدرجة أهمية ٨ من 10. المصدر: GlobeNewswire.


show_chartPrice Chart

Share this article

Copied!

feed SLSN - Latest Insights

SLSN
Mar 31, 2026, 4:52 PM EDT
Filing Type: 10-K
Importance Score:
8
SLSN
Mar 31, 2026, 8:02 AM EDT
Source: GlobeNewswire
Importance Score:
8